Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001731122-25-000724
Filing Date
2025-05-13
Accepted
2025-05-13 16:31:17
Documents
49
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q e6578_10q.htm   iXBRL 10-Q 724368
2 EXHIBIT 31.1 e6578_ex31-1.htm EX-31.1 8315
3 EXHIBIT 31.2 e6578_ex31-2.htm EX-31.2 8186
4 EXHIBIT 32.1 e6578_ex32-1.htm EX-32.1 6226
5 GRAPHIC image_001.jpg GRAPHIC 27513
6 GRAPHIC image_002.jpg GRAPHIC 28496
  Complete submission text file 0001731122-25-000724.txt   3384090

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE avxl-20250331.xsd EX-101.SCH 30154
8 XBRL CALCULATION FILE avxl-20250331_cal.xml EX-101.CAL 25801
9 XBRL DEFINITION FILE avxl-20250331_def.xml EX-101.DEF 84134
10 XBRL LABEL FILE avxl-20250331_lab.xml EX-101.LAB 247999
11 XBRL PRESENTATION FILE avxl-20250331_pre.xml EX-101.PRE 191471
51 EXTRACTED XBRL INSTANCE DOCUMENT e6578_10q_htm.xml XML 392722
Mailing Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111
Business Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111 844-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 980608404 | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37606 | Film No.: 25940669
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)